secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2022-10-11T23:59:59+00:00
Accession:  0001851734-22-000600
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex expands Nestlé Health Science supply deal to supplements; Nestlé invests $5M
--------------------------------------------------------------------------------

- New 5-year supply agreement gives Nestlé non-exclusive rights to sell Niagen in dietary supplements, medical nutrition, and functional foods.
- Nestlé commits to initial $1.975M Niagen purchase in 2022; ChromaDex eligible for low-single-digit royalties and low-seven-figure milestone payments.
- Nestlé purchases 3,816,794 shares of CDXC at ~$1.31/share for $5M in a registered direct offering.
- Agreement expands prior 2018 deal; term automatically extends if minimum purchase met.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000185173422000600/0001851734-22-000600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000185173422000600/cdxc20221007_8k.htm
  HTML page:      https://secwatch.observer/filing/0001851734-22-000600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer